pp-272 Solution for injection/infusion
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Myocardial disease, Heart disease
Clinical stage: Phase 2
Modality: Peptide
Mechanism & Target: Immunomodulator
Route & form: SC injection / IV infusion
Differentiation: Not disclosed
Manufacturer #39683
A clinical-stage biopharmaceutical company focused on cardiovascular. Developing a biologic therapeutic targeting cardiovascular with global development focus. Pipeline positioned for regulatory advancement in key markets.
None